Abstract
Cancer immunotherapy blocking immune checkpoints represents a major advance in oncology. Immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death 1 (PD-1) or its ligand PD-L1...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have